PHARMACEUTICALS & BIOTECHNOLOGY
ARKIN BIO VENTURES
Arkin Bio Ventures identifies, invests in, and accompanies innovative early and mid-stage companies with game-changing breakthroughs in areas such as: immunotherapy, cancer, metabolism, microbiome, CNS, autoimmune diseases, orphan diseases and drug delivery platforms.
The experienced Arkin Bio Ventures’ management team, leads and supports its portfolio companies through the hurdles of drug development, towards the proof of concept stage and beyond, to significant value creation.
Arkin Bio Ventures is currently invested in companies in various stages of product development. It recently sold cCAM Biotherapeutics, an immune-oncology company, to Merck for $605 million.